Literature DB >> 29673715

Optimized allosteric inhibition of engineered protein tyrosine phosphatases with an expanded palette of biarsenical small molecules.

Samuel Korntner1, Adam Pomorski2, Artur Krężel2, Anthony C Bishop3.   

Abstract

Protein tyrosine phosphatases (PTPs), which catalyze the dephosphorylation of phosphotyrosine in protein substrates, are important cell-signaling regulators, as well as potential drug targets for a range of human diseases. Chemical tools for selectively targeting the activities of individual PTPs would help to elucidate PTP signaling roles and potentially expedite the validation of PTPs as therapeutic targets. We have recently reported a novel strategy for the design of non-natural allosteric-inhibition sites in PTPs, in which a tricysteine moiety is engineered within the PTP catalytic domain at a conserved location outside of the active site. Introduction of the tricysteine motif, which does not exist in any wild-type PTP, serves to sensitize target PTPs to inhibition by a biarsenical compound, providing a generalizable strategy for the generation of allosterically sensitized (as) PTPs. Here we show that the potency, selectivity, and kinetics of asPTP inhibition can be significantly improved by exploring the inhibitory action of a range of biarsenical compounds that differ in interarsenical distance, steric bulk, and electronic structure. By investigating the inhibitor sensitivities of five asPTPs from four different subfamilies, we have found that asPTP catalytic domains can be broadly divided into two groups: one that is most potently inhibited by biarsenical compounds with large interarsenical distances, such as AsCy3-EDT2, and one that is most potently inhibited by compounds with relatively small interarsenical distances, such as FlAsH-EDT2. Moreover, we show that a tetrachlorinated derivative of FlAsH-EDT2, Cl4FlAsH-EDT2, targets asPTPs significantly more potently than the parent compound, both in vitro and in asPTP-expressing cells. Our results show that biarsenicals with altered interarsenical distances and electronic properties are important tools for optimizing the control of asPTP activity and, more broadly, suggest that diversification of biarsenical libraries can serve to increase the efficacy of these compounds in targeted control of protein function.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AsCy3; Enzyme inhibition; FlAsH; Protein engineering; Protein tyrosine phosphatases

Mesh:

Substances:

Year:  2018        PMID: 29673715      PMCID: PMC5935566          DOI: 10.1016/j.bmc.2018.04.026

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  28 in total

Review 1.  Structural and evolutionary relationships among protein tyrosine phosphatase domains.

Authors:  J N Andersen; O H Mortensen; G H Peters; P G Drake; L F Iversen; O H Olsen; P G Jansen; H S Andersen; N K Tonks; N P Møller
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

Review 2.  Novel chemical genetic approaches to the discovery of signal transduction inhibitors.

Authors:  Kevan Shokat; Mark Velleca
Journal:  Drug Discov Today       Date:  2002-08-15       Impact factor: 7.851

3.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

Review 4.  Drug discovery and protein tyrosine phosphatases.

Authors:  Mark A T Blaskovich
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

5.  Specific covalent labeling of recombinant protein molecules inside live cells.

Authors:  B A Griffin; S R Adams; R Y Tsien
Journal:  Science       Date:  1998-07-10       Impact factor: 47.728

6.  Fluorescent probes for selective protein labeling in lysosomes: a case of α-galactosidase A.

Authors:  Cornelius Bohl; Adam Pomorski; Susanne Seemann; Anne-Marie Knospe; Chaonan Zheng; Artur Krężel; Arndt Rolfs; Jan Lukas
Journal:  FASEB J       Date:  2017-08-15       Impact factor: 5.191

7.  Activation of Engineered Protein Tyrosine Phosphatases with the Biarsenical Compound AsCy3-EDT2.

Authors:  Wai Cheung Chan; Gregory S Knowlton; Anthony C Bishop
Journal:  Chembiochem       Date:  2017-08-23       Impact factor: 3.164

Review 8.  Protein tyrosine phosphatase function: the substrate perspective.

Authors:  Tony Tiganis; Anton M Bennett
Journal:  Biochem J       Date:  2007-02-15       Impact factor: 3.857

9.  Crystal structure of human protein tyrosine phosphatase 1B.

Authors:  D Barford; A J Flint; N K Tonks
Journal:  Science       Date:  1994-03-11       Impact factor: 47.728

10.  Targeting a cryptic allosteric site for selective inhibition of the oncogenic protein tyrosine phosphatase Shp2.

Authors:  Cynthia M Chio; Christopher S Lim; Anthony C Bishop
Journal:  Biochemistry       Date:  2015-01-02       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.